| 引用本文： |
-
左晓佳,冯尽意,叶丽霖,等.新免疫标志组合在多参数流式细胞术检测多发性骨髓瘤微小残留病中的应用[J].同济大学学报（医学版）,2020,41(6):722-728. [点击复制]
- ZUO Xiao-jia,FENG Jin-yi,YE Li-lin,et al.Application of new combination of immune markers in detection of minimal residual disease in patients with multiple myeloma[J].同济大学学报（医学版）,2020,41(6):722-728. [点击复制]
|
|
| 摘要: |
| 目的多参数流式细胞术（multiparameter flow cytometry, MFC）检测多发性骨髓瘤（multiple myeloma, MM）微小残留病(minimal residual disease, MRD)细胞和非MM浆细胞两者免疫标志表达的区别。方法2012年4月至2020年4月淮安市第一人民医院和上海健康医学院附属周浦医院收治的44例具有MRD的MM患者和43例非MM患者分别为研究组和对照组，应用10色流式细胞仪检测浆细胞CD45、CD19、CD56、CD28、CD117、CD20以及CD44、CD49d和CD184表达情况。结果与非MM浆细胞高表达不同，MM的MRD细胞中CD44为低表达，两类细胞的表达差异有统计学意义（P=0.007），CD44可能是MM检测MRD免疫标志之一；CD49d和CD184广泛存在于MM的MRD细胞和非MM浆细胞中，但缺乏特异性，不能作为MM特异性免疫标志；利用CD45、CD19、CD56、CD28、CD117、CD20和CD44的界值判断免疫标志的异常个数，MM的MRD细胞中位异常免疫标志数为4(2~6)个，而非MM浆细胞为0(0~2)个。结论通过MFC检测新的免疫标志组合CD45、CD19、CD56、CD28、CD117、CD20和CD44可以有效的鉴别出MM的MRD细胞。 |
| 关键词: 浆细胞 多发性骨髓瘤 多参数流式细胞术 微小残留病 |
| DOI：10.16118/j.1008-0392.2020.06.007 |
| 投稿时间：2020-05-18 |
| 基金项目:浦东新区卫生系统学科带头人培养计划（PWRd2015-09）；上海健康医学院师资人才百人库项目（ZPBRK-19-01） |
|
| Application of new combination of immune markers in detection of minimal residual disease in patients with multiple myeloma |
| ZUO Xiao-jia,FENG Jin-yi,YE Li-lin,XING Miao,DENG Zhi-kui,LIU Ding-sheng |
| (Guizhou Medical University, Guiyang 550004, China;Dept. of Oncology and Hematology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China;Dept. of Hematology, Huai’an First People’s Hospital, Huai’an 223000, Jiangsu Province, China) |
| Abstract: |
| ObjectiveTo investigate the new combination of immune markers in detection of the minimal residual disease(MRD) in patients with multiple myeloma(MM). MethodsForty-four MM patients with MRD and 43 non-MM patients admitted to the Huai’an First People’s Hospital and Zhoupu Hospital from April 2012 to April 2020 were enrolled in the study. Immune markers CD45, CD19, CD56, CD28, CD117, CD20, CD44, CD49d and CD184 were detected by 10-color flow cytometry in plasma cells of all patients. ResultsThe expression of CD44 in MRD cells of MM group was significantly lower than that in plasma cells of non-MM group(P=0.007). There were no significant difference in expression of CD49d and CD184 between MM and non-MM groups. By using the cut-off value of CD45, CD19, CD56, CD28, CD117, CD20 and CD44, the number of abnormal immune markers of MRD cells in MM group was 4(range, 2-6), while the number of plasma cells in non-MM group was 0(range, 0-2). ConclusionThe new combination of immune markers(CD45, CD19, CD56, CD28, CD117, CD20 and CD44) detected by multi-parameter flow cytometer may effectively identify the MRD cells in MM patients. |
| Key words: plasma cells multiple myeloma multi-parameter flow cytometry minimal residual disease |
